- Elexacaftor/tezacaftor/ivacaftor, sold
under the
brand names Trikafta and Kaftrio, is a fixed-dose
combination medication used to
treat cystic fibrosis...
-
application was
filed with it, the FDA
approved Vertex's Triple-combo
therapy Trikafta (elexacaftor/tezacaftor/ivacaftor) for
patients 12 and
older with at least...
- the fixed-dose combination, elexacaftor/tezacaftor/ivacaftor (brand name
Trikafta), is used to
treat people with
cystic fibrosis who are
homozygous for the...
- The
combination of
tezacaftor with
elexacaftor and
ivacaftor (brand name
Trikafta) was
approved for
medical use in the
United States in
October 2019, and...
- 2019, the
combination drug elexacaftor/ivacaftor/tezacaftor,
marketed as
Trikafta and
described as
modulator therapy, was
approved for CF
patients over the...
- drug to the
pipeline as
Vertex seals its
domination of the
field with
Trikafta OK". EndpointNews.
University of Kansas. Hopkins,
Jared S. (February 6...
-
available in a
combination product with
elexacaftor and
tezacaftor called Trikafta for the
treatment of
people with
cystic fibrosis who have the F508del mutation...
-
constituents with
cystic fibrosis to
grant access to new life-saving
drugs like
Trikafta,
making sure it's on the list of Alberta-approved drugs.
After the Alberta...
- for the
company Vertex Pharmaceuticals,
which makes cystic fibrosis drug
Trikafta.
Stephenson has been a
member of ACT for
nearly 30 years,
since its formation...
-
Since she
became CEO,
Vertex has
developed cystic fibrosis therapy drug
Trikafta, APOL1-mediated
kidney disease experimental apolipoprotein L1 inhibitor...
